Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KAI 4729

Next Previous
Drug Profile

KAI 4729

Alternative Names: HRS-4729; KAI-4729

Latest Information Update: 11 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Jiangsu Hengrui Medicine Co.; Kailera Therapeutics
  • Class Antihyperglycaemics; Obesity therapies; Peptides
  • Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Obesity
  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 08 Sep 2026 Fujian Shengdi Pharmaceutical plans a phase I trial for Obesity (In volunteers) in China (SC, Injection) in September 2026 (NCT07807059)
  • 22 Jun 2026 Fujian Shengdi Pharmaceutical plans a phase II trial for Metabolic Dysfunction-Associated Steatohepatitis in China in July 2026 (Parenteral, Injection) (NCT07660848)
  • 27 May 2026 Efficacy, pharmacokinetics and adverse events data from a phase I trial in Obesity released by Jiangsu Hengrui Medicine

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top